0IT Stock Chart & Stats
€7.75
€0.05(0.60%)
At close: 4:00 PM EDT
€7.75
€0.05(0.60%)
Day’s Range― - ―
52-Week Range€4.56 - €11.38
Previous CloseN/A
Volume0.00
Average Volume (3M)11.00
Market Cap
€142.20M
Enterprise Value€134.33M
Total Cash (Recent Filing)€61.74M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Nov 25, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding21,216,438
10 Day Avg. Volume35
30 Day Avg. Volume11
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)4.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.13Price Target Upside185.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet reduces interest and refinancing pressure while preserving financial flexibility. Meaningful equity provides a cushion for continued development spending and gives management more capacity to allocate capital without the constraints associated with leverage.
Focused Regenerative Medicine ProgramThe company has a clearly defined therapeutic focus rather than a broadly dispersed pipeline, concentrating resources on regenerative medicine for skeletal muscle disorders. A focused program can improve development discipline and support consistent strategic execution as clinical work progresses.
Recent Moderation In Cash-flow DeteriorationThe improvement in free-cash-flow growth indicates that the pace of deterioration has recently moderated, which could support better spending control over the next several quarters. This is a limited positive because absolute cash generation remains negative and requires continued monitoring.
Bears Say
No Revenue And Widening LossesThe absence of revenue means the business has not yet demonstrated commercial traction or operating leverage, while widening losses show that spending is increasing ahead of product monetization. Until revenue emerges, profitability remains dependent on continued external funding capacity.
Sustained Cash BurnPersistent negative operating and free cash flow shows that reported losses translate into substantial real cash outflows. Continued burn can reduce financial resources available for clinical development and may eventually require additional capital to sustain operations and advance the pipeline.
Losses Eroding Shareholder ValueA deeply negative return on equity indicates that current operations are destroying rather than generating value from the capital invested in the company. Equity volatility alongside ongoing losses signals that the balance-sheet cushion can weaken over time if development spending continues without revenue.
Satellos Bioscience News
0IT FAQ
What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was €4.56 and its highest was €11.38 in the past 12 months.
What is Satellos Bioscience’s market cap?
Satellos Bioscience’s market cap is €142.20M.
When is Satellos Bioscience’s upcoming earnings report date?
Satellos Bioscience’s upcoming earnings report date is Nov 25, 2026 which is in 45 days.
How were Satellos Bioscience’s earnings last quarter?
Satellos Bioscience released its earnings results on Aug 13, 2026. The company reported -€0.486 earnings per share for the quarter, missing the consensus estimate of -€0.454 by -€0.033.
Is Satellos Bioscience overvalued?
According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued.
Does Satellos Bioscience pay dividends?
Satellos Bioscience does not currently pay dividends.
What is Satellos Bioscience’s EPS estimate?
Satellos Bioscience’s EPS estimate is -0.53.
How many shares outstanding does Satellos Bioscience have?
Satellos Bioscience has 21,216,438 shares outstanding.
What happened to Satellos Bioscience’s price movement after its last earnings report?
Satellos Bioscience reported an EPS of -€0.486 in its last earnings report, missing expectations of -€0.454. Following the earnings report the stock price went up 0.592%.
Which hedge fund is a major shareholder of Satellos Bioscience?
Currently, no hedge funds are holding shares in DE:0IT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Satellos Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€22.13 (185.60% Upside)
€22.13 (185.60% Upside)
Insider Transactions
Bought Shares
Worth €107.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.76%
12-Months-Change
Fundamentals
Return on Equity
-72.67%
Trailing 12-Months
Asset Growth
59.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Satellos Bioscience
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
0IT Stock 12 Month Forecast
Average Price Target
€22.13
▲(185.60% Upside)
Technical Analysis
Arch Biopartners
―
Medicenna Therapeutics Corp
―
Helix BioPharma
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―